How India Exports Cefixime to the World

In the United States, cefixime is approved for use and is listed in the FDA's Orange Book. The regulatory pathway for cefixime involves the submission of an Abbreviated New Drug Application (ANDA) to the FDA, demonstrating bioequivalence to the reference listed drug. As of March 2026, there are multiple approved ANDAs for cefixime, indicating a competitive market with several generic manufacturers. Notably, Indian exporters have a significant presence in the U.S. market, with 7.1% of India's cefixime exports directed to the United States. This underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and ensuring product quality to maintain market access.

In the European Union (EU) and the United Kingdom (UK), cefixime is subject to stringent regulatory oversight. Marketing authorization requires compliance with the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) standards. In March 2026, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updating the product information for cefixime to include warnings about potential encephalopathy risks. This decision followed a periodic safety update report (PSUR) assessment, highlighting the need for continuous monitoring and prompt incorporation of safety information into product labeling. Manufacturers exporting to these regions must ensure compliance with EU Good Manufacturing Practice (GMP) guidelines and stay informed about regulatory updates to maintain market authorization.

Cefixime is included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its importance in treating bacterial infections. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of cefixime, facilitating its acceptance in global markets.

In India, cefixime is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including cefixime, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations and monitoring of drug exports.

The primary patents for cefixime have expired, leading to the availability of generic versions and increased competition in the market. This has resulted in a diversified exporter base, with 668 active Indian exporters supplying cefixime to various international markets.

In March 2026, the EMA's PRAC recommended updating cefixime's product information to include warnings about potential encephalopathy risks, emphasizing the need for manufacturers to stay vigilant about safety updates. Additionally, in January 2026, the FDA approved a new generic version of cefixime, further intensifying market competition. These developments highlight the dynamic nature of the pharmaceutical industry and the importance of regulatory compliance and market awareness for exporters.

Cefixime, a third-generation cephalosporin antibiotic, is primarily manufactured in India, which has established itself as a significant producer of Active Pharmaceutical Ingredients (APIs). However, the production of Cefixime heavily relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This dependency poses a substantial risk, as any disruption in China's supply chain can directly impact the availability and cost of Cefixime APIs.

Recent geopolitical tensions and trade disputes have further highlighted the vulnerabilities associated with this reliance. For instance, in June 2025, the U.S. doubled Section 232 tariffs on steel and aluminum imports, which indirectly affected pharmaceutical supply chains by increasing production costs for equipment and materials. (pharmasource.global) Such events underscore the need for diversification in sourcing strategies to mitigate potential disruptions.

Our proprietary trade data indicates that the top five Indian exporters of Cefixime account for 30.4% of the total export value, with MICRO LABS LIMITED leading at an 11.0% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could impact global supply chains. To address such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical APIs and reduce dependency on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-reliance.

Geopolitical tensions have notably impacted pharmaceutical supply chains. In June 2025, combined U.S.-Israeli strikes on Iranian energy sites led to a surge in Brent crude oil prices to $80 per barrel, escalating utility costs and pressuring manufacturing margins. (pharmasource.global) Additionally, the Strait of Hormuz, a critical chokepoint for global shipping, has been a focal point of geopolitical conflicts, posing risks to the timely delivery of pharmaceutical products. Furthermore, the U.S. Food and Drug Administration (FDA) has issued alerts regarding drug shortages, emphasizing the need for robust supply chain strategies to ensure uninterrupted access to essential medications.

• Diversify Sourcing: Identify and qualify alternative suppliers for KSMs and APIs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Leverage government initiatives like the PLI scheme to invest in local manufacturing capabilities for critical pharmaceutical ingredients.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify potential disruptions early and respond proactively.

• Develop Strategic Stockpiles: Establish reserves of essential APIs and KSMs to buffer against short-term supply interruptions.

• Engage in Policy Advocacy: Collaborate with industry associations and regulatory bodies to advocate for policies that support supply chain diversification and resilience.

RISK_LEVEL: MEDIUM